Journal of Medicinal Chemistry · 2008 · 41 citations · 12 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryNeuropharmacologyStructure-activity RelationshipsHit-to-lead OptimizationLead Compound DesignLead DiscoveryReceptor PharmacologySolubility OptimizationStructure-activity Relationship AnalysisAqueous Solubility ImprovementAqueous Solubility OptimizationChemical Structure-activity RelationshipsChemical Synthesis Of AnaloguesIn Vivo Efficacy TestingParkinson's Disease ModelsParkinson's Disease PharmacotherapyParkinson’s Disease Pharmacotherapy
Potent adenosine hA2A receptor antagonists are often accompanied by poor aqueous solubility, which presents issues for drug development. Herein we describe the early exploration of the structure-activity relationships of a lead pyrimidin-4-yl acetamide series to provide potent and selective 2-amino-N-pyrimidin-4-yl acetamides as hA2A receptor antagonists with excellent aqueous solubility. In addition, this series of compounds has demonstrated good bioavailability and in vivo efficacy in a rodent model of Parkinson's disease, despite having reduced potency for the rat A2A receptor versus the human A2A receptor.
12
Tomoyuki Kanda, Lance A. Smith, R. K. B. Pearce et al. · Experimental Neurology · 2000 · 246 citations
Patrizia Popoli, Annita Pintor, Maria Rosaria Domenici et al. · Journal of Neuroscience · 2002 · 216 citations · Full text